Protalix BioTherapeutics (PLX) Competitors $1.95 +0.04 (+2.09%) Closing price 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.51%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. ZVRA, PRME, BCYC, EOLS, REPL, CMPS, RGNX, ARCT, CMPX, and ETONShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), Replimune Group (REPL), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Zevra Therapeutics Prime Medicine Bicycle Therapeutics Evolus Replimune Group COMPASS Pathways REGENXBIO Arcturus Therapeutics Compass Therapeutics Eton Pharmaceuticals Zevra Therapeutics (NASDAQ:ZVRA) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations. Do insiders and institutionals believe in ZVRA or PLX? 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate ZVRA or PLX? Zevra Therapeutics presently has a consensus price target of $23.71, suggesting a potential upside of 226.64%. Protalix BioTherapeutics has a consensus price target of $15.00, suggesting a potential upside of 669.23%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, ZVRA or PLX? Protalix BioTherapeutics has lower revenue, but higher earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$62.02M6.57-$105.51M-$0.21-34.57Protalix BioTherapeutics$61.95M2.51$8.31M$0.0727.86 Is ZVRA or PLX more profitable? Zevra Therapeutics has a net margin of 4.33% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics4.33% -112.40% -37.67% Protalix BioTherapeutics -21.03%-30.89%-11.74% Does the media favor ZVRA or PLX? In the previous week, Zevra Therapeutics had 6 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 7 mentions for Zevra Therapeutics and 1 mentions for Protalix BioTherapeutics. Zevra Therapeutics' average media sentiment score of 1.27 beat Protalix BioTherapeutics' score of 0.78 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protalix BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ZVRA or PLX? Zevra Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500. SummaryZevra Therapeutics and Protalix BioTherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$155.48M$291.50M$5.69B$21.37BDividend YieldN/AN/A5.72%3.49%P/E Ratio-15.00N/A75.8629.83Price / Sales2.51431.33489.9288.70Price / Cash17.8022.4425.8118.13Price / Book4.1510.4412.844.58Net Income$8.31M-$111.61M$3.28B$998.53M7 Day Performance13.37%-2.02%0.20%1.07%1 Month Performance31.76%3.60%4.59%4.41%1 Year Performance78.90%-14.21%68.31%14.45% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.3331 of 5 stars$1.95+2.1%$15.00+669.2%+81.9%$155.48M$61.95M-15.00200ZVRAZevra Therapeutics2.9944 of 5 stars$8.33-6.9%$23.71+184.7%-7.9%$502.41M$23.61M-39.6720Positive NewsAnalyst DowngradeGap UpPRMEPrime Medicine3.3167 of 5 stars$3.89+4.6%$8.92+129.2%-2.0%$500.62M$4.96M-1.90234BCYCBicycle Therapeutics3.5071 of 5 stars$7.00-2.2%$22.22+217.5%-74.6%$495.86M$35.28M-1.99240EOLSEvolus4.0519 of 5 stars$7.61-0.7%$21.25+179.2%-62.1%$495.49M$266.27M-7.77170REPLReplimune Group3.8485 of 5 stars$6.04-4.6%$6.50+7.6%-49.1%$494.09MN/A-1.86210Trending NewsCMPSCOMPASS Pathways3.0939 of 5 stars$4.98-3.1%$16.29+227.0%-29.1%$493.14MN/A-2.71120Positive NewsRGNXREGENXBIO4.5855 of 5 stars$9.48-2.4%$28.38+199.3%-29.2%$490.49M$83.33M-2.76370ARCTArcturus Therapeutics2.8631 of 5 stars$17.84-0.1%$50.57+183.5%-12.6%$484.72M$109.80M-8.00180News CoveragePositive NewsCMPXCompass Therapeutics2.2437 of 5 stars$3.44flat$12.89+274.7%+123.6%$475.69M$850K-7.6420ETONEton Pharmaceuticals2.2952 of 5 stars$17.78+0.6%$29.67+66.9%+245.2%$473.87M$39.01M-111.1320News CoveragePositive News Related Companies and Tools Related Companies Zevra Therapeutics Alternatives Prime Medicine Alternatives Bicycle Therapeutics Alternatives Evolus Alternatives Replimune Group Alternatives COMPASS Pathways Alternatives REGENXBIO Alternatives Arcturus Therapeutics Alternatives Compass Therapeutics Alternatives Eton Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored$4?In times like these… it’s almost impossible to find a good deal. That’s why you should check this out. G...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
